Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

This is a prospective, open-label, phase 2 platform trial. The purpose of this study is to test the safety and effectiveness of the antibody-conjugated drugs (ADCs) in patients with advanced breast cancer who had previously used antibody-conjugated drugs.

Trial Details

NCT ID

NCT06649331

Phase

PHASE2

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

SHR-A1811
SHR-A1921
SHR-A2009
SHR-A2102
Famitinib
Fat Module Formula for Special Medical Purposes

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Age ≥18 years;
Locally advanced breast cancer (unable to undergo radical local treatment) or recurrent metastatic breast cancer;
Previously received ADCs;
The most recent pathology results will be considered for enrollment according to local testing of ER, PR and HER2. Participants with any hormone re…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →